{"entity":{"id":"paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021","kind":"paper","name":"CSCO and ASCO guideline: chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II to IVA nasopharyngeal carcinoma","aka":[],"tldr":"The joint Chinese and American guideline on when to add chemotherapy to radiotherapy for nasopharyngeal cancer: concurrent cisplatin for most stage II to IVA disease, induction gemcitabine-cisplatin for higher-risk disease, and how to handle patients who cannot take cisplatin.","summary":"Evidence-based guideline from the Chinese Society of Clinical Oncology and the American Society of Clinical Oncology based on a systematic review of randomised trials in stage II to IVA nasopharyngeal carcinoma, recommending concurrent cisplatin chemoradiotherapy, induction chemotherapy (gemcitabine-cisplatin preferred) for stage III to IVA disease with high-risk features, adjuvant chemotherapy in selected patients, and alternatives for cisplatin-ineligible patients, with cumulative cisplatin dose targets.","asOf":"2026-09-18","links":[{"label":"J Clin Oncol 2021","url":"https://doi.org/10.1200/JCO.20.03237"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33405943/"}],"tags":[],"related":[],"cancers":["locoregionally-advanced-nasopharyngeal-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cisplatin","gemcitabine-cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/JCO.20.03237","pmid":"33405943","authors":"Chen YP, Ismaila N, Chua MLK, et al.","paperType":"guideline","findings":[],"whatItMeans":"The standard-of-care rows on the locoregionally advanced nasopharyngeal page follow this guideline.","caveats":["Predates trials adding PD-1 antibodies to chemoradiotherapy and metronomic capecitabine adjuvant therapy.","Most evidence comes from endemic regions."],"changedPractice":true},"route":"/key-papers/paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021/","neighbours":{"cancer":[{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}